Article information
Full text is only aviable in PDF
Bibliografía
[2.]
British Thoracic Society, Research Unit of the Royal College of Physicians of London, King's Fund Centre, National Asthma, Campaign.
Guidelines for the management fo asthma in adults.
Br Med J, 301 (1990), pp. 651-653
[3.]
NIH International Consensus Report.
Report on diagnosis and treatment of asthma.
US Department of Health and Human Services, National Institute of Health, (1992),
[4.]
National Institutes of Health.
Global Strategy for asthma management and prevention: NHLBI/WHO Workshop Report.
Eds. NIH Publication N.° 95-3659, (1995), pp. 76-77
[6.]
R.A. Thompson.
The current status of allergen immunotherapy (hyposensitisation).
Report of WHO/IUIS working group. Allergy, 44 (1989), pp. 369-379
[7.]
H.J. Mailing, B. Weeke.
Position paper: immunotherapy.
Allergy, 14 (1993), pp. 7-49
[8.]
L. Cardóniga, G. Marino, M.A. Sandoval, N. Martín.
Consumo de extractos hiposensibilizantes y vacunas bacterianas.
Información Terapéutica del Sistema Nacional de Salud, 14 (1990), pp. 333-347
[9.]
Alergológica 92.
Sociedad Española de Alergología e Inmunología Clínica.
Alergia e Inmunología, pp. 58-59
[10.]
J.F. Price, J.O.P. Warner, E.N. Hey, M.W. Turner, J.F. Soothil.
A controlled trial of hyposensitization with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma: In vivo aspects.
Clin Allergy, 14 (1984), pp. 209-220
[11.]
E. Alvarez Cuesta, A. Beristain.
Inmunoterapia y desensibilización.
Inmunoterapia general. Tratado de alergología e inmunología clínica (Tomo II), pp. 515-580
[12.]
R.A. Cooke.
The preparation and standaridization of pollen extracts for the treatment of hay fever.
J Allergy, 4 (1933), pp. 87
[13.]
K. Aas, A. Backman, L. Belin, B. Weeke.
Standaridization of allergen extracts with appropriate methods. The combined use of skin prick testing and radioallergosorbent test.
Allergy, 33 (1978), pp. 130-137
[14.]
W.D. Brighton, M.D. Topping, E. Henocq.
Activity units for allergen extracts.
Clin Allergy, 9 (1979), pp. 591-596
[15.]
P.C. Turkeltaub, S.C. Rastogi, H. Baer, M.C. Anderson, P.S. Norman.
A standardized quantitative skin-test array of allergen potency and stability: studies on the allergen dose response curve and effect of wheal, erythema and patient selection on assay results.
J Allergy Clin Immunol, 70 (1982), pp. 343-352
[16.]
Nordin Council on Medicines.
Registration of allergenic preparations.
nordic guidelines, 2.a, NLN Publications, (1989), pp. 1-347
[17.]
F. Duce.
Inmunoterapia en el asma bronquial.
Arch Bronconeumol, 26 (1990), pp. 137-139
[18.]
T.E. Van Metre, N.E. Adkinson.
Immunotherapy for aeroallergen disease. En: Middleton E, Reed CE, Ellis F, editores.
Allergy. Principles and practice, Cv Mosby, (1993), pp. 1.489-1.509
[19.]
E. Alvarez Cuesta, J. Cuesta, J. Puyana, C. Herranz, A. Blanco Quirós.
Monoclonal antibody-standaridized cat extract immunotherapy: risk benefit effects from a double-blind placebo study.
J Allergy Clin Immunol, 93 (1994), pp. 556-566
[20.]
J. Bousquet, F.B. Michel.
Specific immunotherapy: past, present and future.
Allergologie, 12 (1989), pp. 193-197
[21.]
J. Oppenheimer, J.G. Areson, H.S. Nelson.
Safety and efficacy of oral immunotherapy with standardized cat extract.
J Allergy Clin Immunol, 93 (1994), pp. 61-67
[22.]
H. Mosbech, S. Dreborg, F. Madsen, H. Ohlsson, P. Stahl Skov, E. Taudorf, et al.
High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year placebo controlled study.
Allergy, 42 (1987), pp. 451-455
[23.]
V.A. Varney, M. Gaga, A.J. Frew, V.R. Aber, A.B. Kay, S.R. Durham.
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by anti-allergy drugs.
Brit M I, 302 (1991), pp. 265-269
[24.]
G. Hedlin, G. Silber, R.M. Naeleiro, D. Proud, A.M. Lamas, P. Egleston.
Comparison of the in vivo and in vitro response to radweed immunotherapy in children and adults with radwe-induced rhinitis.
Clin Exp Allergy, 20 (1990), pp. 491-500
[25.]
R. Djurup, H.J. Mailing.
High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens.
Clin Allergy, 17 (1987), pp. 459-468
[26.]
S.M. McHugh, M. Lavelle, D.M. Kemeny, S. Patel, P.W. Ewan.
A placebo-controlled trial of immunotherapy with two extracts of D. pteronyssinus in allergy rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG and IgG subclasses.
J Allergy Clin Immunol, 86 (1990), pp. 521-532
[27.]
O. Iliopoulos, D. Proud, N.F. Atkinson.
Effects of immunotherapy on the early, late an rechallenge nasal reaction to provocation with allergen: changes in inflammatory mediators and cells.
J Allergy Clin Immunol, 87 (1991), pp. 855-866
[28.]
S.M. Me Hugh, P.W. Ewan.
Reduction of increse serum neutrophil chemotactic activity following effective hyposensitization in house dust mite allergy.
Clin Exp Allergy, 19 (1989), pp. 327-334
[29.]
M.J. Furin, P.S. Norman, P.S. Creticos, D. Proud, A. Kagey-Sobotka.
Immunotherapy decreases antigen-induced eosinophil cell migration into the nasal cavity.
J Allergy Clin Immunol, 88 (1991), pp. 27-32
[30.]
S. Rak, O. Löwhagen, P. Venge.
The effect of immunotherapy on.bronchial hyperresponsiveness and eosinophil protein in pollenallergy patients.
J Allergy Clin Immunol, 82 (1988), pp. 480-490
[31.]
Committee on Safety on Medicines.
Desensitizing vaccines.
Br M J, 293 (1986), pp. 948-952
[32.]
M.J. Reid, R.F. Lockey, P.C. Turkeltaub, A.E. Platts-Mills.
Survey of fatalities from skin testing and immunotheraphy 1985-1989.
J Allergy Clin Immunol, 92 (1993), pp. 6-15
[33.]
S. Quirce, Álvarez, E. Cuesta, J. Cuesta.
Seguridad en la inmunoterapia.
Rev Alergol Inmunol Clin, 6 (1991), pp. 42-48
[34.]
A.I. Tabar, B.E. García, A. Rodríguez, J.M. Olaguibel, M.D. Muro, S. Quirce.
A prospective safety-monitoring study of immunotherapy with biologically standardized extracts.
Allergy, 48 (1993), pp. 450-453
[35.]
J. Bousquet, J.H. Maasch, B. Martinot, A. Hejjaoui, R. Waihl, F.B. Michel, et al.
Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. III. Efficacy and safety of unfractionated and high-molecular-weight preparations in rhinoconjunctivitis and asthma.
J Allergy Clin Immunol, 84 (1989), pp. 546-556
[36.]
J. Bousquet, A. Hejjaoui, M. Soussana, F.B. Michel.
Double-blind, placebo controlled immunotherapy with mixed grass-pollen allergoid. IV. Comparison fo the safety and efficacy of two dosages of a high-molecular-weight allergoid.
J Allergy Clin Immunol, 85 (1990), pp. 490-497
[37.]
A. Armentia, A. Blanco, J.M. Martín, E. Alvarez, I. Moneo, J. Carreira.
Rush immunotherapy with a standardized Bermuda grass pollen extract.
Ann Allergy, 63 (1989), pp. 127-135
[38.]
S. Rak, O. Lowhagen, P. Venge.
The effect of immunotherapy on bronchial hyperresponsiveness and eosinophylic cationig protein in pollen-allergy patients.
J Allergy Clin Immunol, 82 (1988), pp. 470-476
[39.]
S. Rak, L. Hakanson, P. Venge.
Immunotherapy abrogates the generations of eosinophil and neutrophil chemotactic activity during pollen season.
J Allergy Clin Immunol, 86 (1990), pp. 706-712
[40.]
P. Créticos.
Immunotherapy of allergy rhinitis and asthma.
Allergy, 48 (1993), pp. 60-65
[41.]
B. De la Hoz.
Rinoconjuntivitis-asma por sensibilidad al polen de Salsola kali (Chenopodiaceae). Aspectos clínicos e inmunológicos y valoración de la inmunoterapia [tesis doctoral].
Universidad Autónoma, (1994),
[43.]
A.P. Smith.
Hyposensitization with Dennatophagoides pteronyssimis antigen. Trial in asthma by house dust.
Br Med J, 4 (1971), pp. 204
[44.]
J. Gaddie, C. Skinner, K.N.V. Palmer.
Hyposensitization with house dust mite vaccine in bronchial asthma.
Br Med J, 2 (1976), pp. 561-562
[45.]
D.A.G. Newton, D.J. Maberly, R. Wilson.
House dust mite hyposensitization.
Br J Dis Chest, 72 (1978), pp. 21-28
[46.]
G. Pauli, J. Bessot, H. Bigot.
Clinical and immunological evaluation of tyrosine adsorbed. D. pteronyssimts extract: a double-blind placebo controlled trial.
J Allergy Clin Immunol, 74 (1984), pp. 524-535
[48.]
J. Bousquet, P. Calvayrac, B. Guerin.
Immunotherapy with a standardized Dennatophagoides pteronyssimts extracts. I. In vivo and in vitro parameters after a short course of treatment.
J Allergy Clin Immunol, 76 (1985), pp. 734-744
[49.]
U. Wahn, G. Schweter, P. Lind, H. Lowestein.
Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssimts extracts prepared from whole mite culture and mite bodies.
J Allergy Clin Immunol, 82 (1988), pp. 360-370
[50.]
A. Lanner, S. Dreborg.
Einarsson R. Immunotherapy response with a highly purified, standardized mite D. farinae preparation [resumen].
J Allergy Clin Immunol, 73 (1984), pp. 141
[51.]
H. Van Bever, W. Stevens.
Evolution of the late asthmatic reaction during immunotherapy and after stopping immunotherapy.
J Allergy Clin Immunol, 86 (1990), pp. 141-146
[52.]
P. García Ortega.
Decrease of skin and bronchial sensitization following sorb intensive mite allergic asthma.
Chest, 103 (1993), pp. 183-187
[53.]
A. Armentia, J.A. Tapias, J.F. Martín, P. Ventas, A. Fernandez.
Immunotherapy with the storage mit Lepidoglyplms destructor.
Allergol Immunopathol, 23 (1995), pp. 211-223
[54.]
J. Bousquet, F.B. Michel.
Specific immunotherapy in asthma.
Allergy Clin Immunol News, 4 (1992), pp. 106-109
[55.]
T.E. Van Metre, D.G. Marsh, N.F. Adkinson.
Immunotherapy for cat asthma.
J Allergy Clin Immunol, 82 (1988), pp. 1 055-1.068
[56.]
E. Álvarez Cuesta, J. Cuesta, T. Carrillo.
Las pruebas de exposición en el seguimiento de la eficacia de la inmunoterapia con neumoalergenos.
Rev Esp Alergol Inmunol Clin, Libro de ponencias, (1988),
[57.]
B. Sundin, G. Lilja.
Graff-Lonnerig. Immunotherapy with partially purified and standardized animal dander extracts.
J Allergy Clin Immunol, 78 (1986), pp. 478-487
[58.]
A. Bertelsen, J.B. Andersen, J. Christensen.
Immunotherapy with dog and cat extracts in children.
Allergy, 44 (1989), pp. 330-335
[59.]
J. Bucur, S. Dreborg, R. Einarson.
Immunotherapy with dog and cat allergens preparations in dog-sensitive and cat-sensitive asthmatics.
Ann Allergy, 62 (1989), pp. 355-361
[60.]
M. Horst, A. Hejjaoui, V. Horst.
Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract.
J Allergy Clin Immunol, 85 (1990), pp. 460-472
[61.]
H.J. Mailing, S. Dreborg, B. Weeke.
Diagnosis and immunotherapy of mould allergy. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum.
Allergy, 41 (1986), pp. 507-519
[62.]
M. Schaeffer, L. Claysisk.
Allergenic extracts: a review of their safety and efficacy.
Ann Allergy, 52 (1984), pp. 2-11
[63.]
R.F. Lockey, L.M. Benedict, P.C. Turkeltaub, S.C. Bukantz.
Fatalities from immunotherapy (IT) and skin testing (ST).
J Allergy Clin Immunol, 79 (1987), pp. 660-677
[64.]
M.J. Hepner, D.R. Ownby, J.A. Andreson.
Risk of systemic reactions in patients taking beta-blocker drugs receiving allergen immunotherapy injections.
J Allergy Clin Immunol, 85 (1990), pp. 407-411
[65.]
W.J. Metzger, E. Turner, R. Patterson.
The safety of immunotherapy during pregnancy.
J Allergy Clin Immunol, 61 (1978), pp. 268-273
[66.]
J. Bousquet, A. Hejjaoui, H. Dhivert, A.M. Clauzel, F.B. Michel.
Specific immunotherapy with a standardized Dennatophagoides pteronyssimts extract. Systemic reactions during the rush protocol in patients from asthma.
J Allergy Clin Immunol, 83 (1989), pp. 797-802
[67.]
Position paper on allergen Immunotherapy.
Report of a BSACI working party. Indications and efficacy of allergen immunotherapy in asthma. Clin Exp Allergy, pp. 7-10
Copyright © 1996. Sociedad Española de Neumología y Cirugía Torácica
